Amylin/Takeda combo the latest casualty in obesity war of attrition
This article was originally published in Scrip
Amylin and Takeda have decided to discontinue the development of the combination therapy for obesity pramlintide plus metreleptin at the Phase II stage, in what they said was a joint decision based on "a commercial reassessment" of the programme.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context